Changes in bone mineral density in women before critical illness: a matched control nested cohort study
The contribution of premorbid bone health to accelerated bone loss following critical illness is unknown. This study compared bone density in women before critical illness to women who did not become critically ill. Overall bone density was similar, although femoral neck bone mass increased immediately prior to critical illness.
The relative contribution of acute and chronic factors to accelerated loss of bone mineral density (BMD) following critical illness is unknown. This study compared the BMD trajectory of women before critical illness to the BMD trajectory of women who did not become critically ill.
This prospective, nested, age- and medication-matched, case-control study compared trajectory of BMD in women in the Geelong Osteoporosis study (GOS) requiring admission to an Australian Intensive Care Unit (ICU) between June 1998 and March 2016, to women not admitted to ICU. The main outcome was age and medication use adjusted change in BMD.
A total of 52 women, with a mean age of 77 ± 9 years were admitted to ICU, predominantly post-surgery (75%), during the study period. A greater age-adjusted annual rate of decline was observed for pre-ICU women compared to no-ICU women for AP spine BMD (−0.010 ± 0.002 g/cm2 vs −0.005 ± 0.002 g/cm2, p = 0.01) over the 15-year study period. In participants with multiple BMDs 2 years before critical illness, a significantly greater increase in femoral neck BMD compared to age- and medication-matched controls was observed (difference in BMD, ICU vs no-ICU = 0.037 ± 0.013 g/cm2, p = 0.006).
In a cohort of women with predominantly surgical ICU admission, bone health prior to critical illness was comparable to age- and medication-matched controls, with a relative increase in femoral neck bone mass immediately prior to critical illness. These findings suggest critical illness-related bone loss cannot be entirely explained as a continuation of pre-morbid bone trajectory.
KeywordsCritical illness Long-term outcomes Osteoporosis Fracture Bone loss Bone mineral density
Substantial contributions to the conception (NO, RB, DC, MB, JP, MK) or design (NO, MB, JP, RB, DC, MK) of the work; or the acquisition, analysis, or interpretation of data (NO, MB, JP, RB, DC, MK) for the work.
Drafting the work or revising it critically for important intellectual content (NO, MB, JP, RB, DC, MK).
Final approval of the version to be published (NO, MB, JP, RB, DC, MK).
Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. (NO, MB, JP, RB, DC, MK).
Compliance with ethical standards
Conflict of interest
- 2.Orford NR, Lane SE, Bailey M, Pasco JA, Cattigan C, Elderkin T, Brennan-Olsen SL, Bellomo R, Cooper DJ, Kotowicz MA (2016) Changes in bone mineral density in the year after critical illness. Am J Respir Crit Care Med 193(7):736–744. https://doi.org/10.1164/rccm.201508-1514OC CrossRefPubMedGoogle Scholar
- 3.Orford NR, Bailey M, Bellomo R, Pasco JA, Cattigan C, Elderkin T, Brennan-Olsen SL, Cooper DJ, Kotowicz MA (2017) The association of time and medications with changes in bone mineral density in the 2 years after critical illness. Crit Care 21(1):69. https://doi.org/10.1186/s13054-017-1657-6 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Van den Berghe G, Baxter RC, Weekers F et al (2002) The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol 56(5):655–669CrossRefGoogle Scholar
- 14.Van den Berghe G, Weekers F, Baxter RC et al (2001) Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary- gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness*. J Clin Endocrinol Metab 86(7):3217–3226PubMedGoogle Scholar
- 15.Van den Berghe G, Wouters P, Weekers F et al (1999) Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone- releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness*. J Clin Endocrinol Metab 84:1311–1323PubMedGoogle Scholar
- 20.Schwetz V, Schnedl C, Urbanic-Purkart T, Trummer C, Dimai HP, Fahrleitner-Pammer A, Putz-Bankuti C, Christopher KB, Obermayer-Pietsch B, Pieber TR, Dobnig H, Amrein K (2017) Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study. Osteoporos Int 28:1–8. https://doi.org/10.1007/s00198-017-4190-1 CrossRefGoogle Scholar
- 25.Bagshaw SM, Stelfox HT, Johnson JA, McDermid RC, Rolfson DB, Tsuyuki RT, Ibrahim Q, Majumdar SR (2015) Long-term association between frailty and health-related quality of life among survivors of critical illness. Crit Care Med 43(5):973–982. https://doi.org/10.1097/CCM.0000000000000860 CrossRefPubMedGoogle Scholar
- 26.Schwetz V, Schnedl C, Urbanic-Purkart T, Trummer C, Dimai HP, Fahrleitner-Pammer A, Putz-Bankuti C, Christopher KB, Obermayer-Pietsch B, Pieber TR, Dobnig H, Amrein K (2017) Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study. Osteoporos Int 28(12):3347–3354. https://doi.org/10.1007/s00198-017-4190-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Kastritis E, Gavriatopoulou M, Dimopoulos MA, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, Pamboucas C, Toumanidis ST, Terpos E (2015) Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. Blood Cancer J 5(6):e319. https://doi.org/10.1038/bcj.2015.45 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Lerchbaum E, Schwetz V, Pilz S, Boehm BO, März W (2013) Association of bone turnover markers with mortality in women referred to coronary angiography: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Osteoporos Int 25(2):455–465. https://doi.org/10.1007/s00198-013-2411-9 CrossRefPubMedGoogle Scholar
- 31.Levinger I, Brennan-Speranza TC, Zulli A, Parker L, Lin X, Lewis JR, Yeap BB (2017) Multifaceted interaction of bone, muscle, lifestyle interventions and metabolic and cardiovascular disease: role of osteocalcin. Osteoporos Int 28:1–9. https://doi.org/10.1007/s00198-017-3994-3 CrossRefGoogle Scholar